Zerbor/iStock via Getty Images
Shares of Allurion (NYSE:ALUR) shot up nearly 160% in afternoon trading Thursday after the company announced positive data for its Allurion Program for weight loss, which features a swallowable gastric balloon and monitoring apps.
The company said a newly published study showed an average lean mass gain of 5.6% in patients on the program, with an average weight loss of 14% at four months. It noted that weight loss programs with GLP-1 drugs often result in the loss of lean muscle mass along with body fat, according to a statement.
The study was published in a special issue of Clinical Nutrition in Metabolic Disorders.